Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer

Table 1

PI3k/Akt/mTOR inhibitors in preclinical and clinical studies.

Drug	Target kinase	Clinical trial phase	𝑁	PR	SD	PFS	References
Preclinical studies
CH5132799	PI3K						[86]
NVP-BEZ235 + RAD001	PI3K/mTOR						[72]
LY294002 + OBP-801/YM753	PI3K/HDAC						[87]
Published studies and abstracts
Temsirolimus	mTOR	Phase II	19	7–26%	44–69%	4.3 months	[65, 88]
Ridaforolimus	mTOR	Phase II	45, 34	7%	26–53%	16 weeks	[67, 68]
Everolimus	mTOR	Phase II	35	57%	43%	≥8 weeks	[64]
MKC-1		Phase II	9	55.5%	44.4%	1.8 weeks	[85]
Temsirolimus + megestrol + tamoxifen	mTOR	Phase II	22				[82]
Everolimus + letrozole	mTOR	Phase II	28			≥8 weeks	[83]
Ridaforolimus versus medroxyprogesterone versus chemotherapy	mTOR	Phase II	53		35% versus 17%	3.6 versus 1.9 months	[84]

 ^∗𝑁: number of patients; PFS: progression free survival; PR: partial response; SD: stable disease.